BCIDP Credit from the 23rd Annual MAD-ID Meeting

Five (5) hours of Board Certified Infectious Diseases Pharmacist (BCIDP) Recertification Credit is being offered at the 23rd Annual MAD-ID Meeting through a partnership with the Society of Infectious Diseases Pharmacists. Pre-registration for BCIDP credit is recommended, but may be completed after attending MAD-ID.

Sessions offering BCIDP credit are:

  • The Public Health Crisis of Vaccines (presented by Jeff Goad and Daniel Solomon)
  • Disease State Guideline Updates (presented by Emily Spivak and Tom File)
  • Emerging and Difficult to Treat Infections (presented by Wendy Bullington and Jeff Rybak)  

Participants must attend all three sessions (1.5 hr each) and complete an online post-test and evaluation (estimated additional time is .5 hours) to receive a total of 5 BCIDP recertification credit hours.

You must register for and attend MAD-ID to be eligible for BCIDP recertification credit. Register for MAD-ID here: https://mad-id.org/2020-mad-id-annual-meeting/registration-2/ 

Cancellation Policy: ProCE will provide refunds of BCIDP recertification credit fees according to the following time frames with written notice of cancellation:
Before March 27th – full refund, less a $40 administrative fee
March 28th– April 27th – 50% of your fee will be refunded
April 28th – forward, no refunds will be processed

Learning Objectives

The target audience for this activity includes board-certified infectious diseases pharmacists (BCIDPs) seeking to update their knowledge and skills related to contemporary infectious diseases literature review. 

A Public Health Crisis: Vaccines [May 29, 8:00-9:30am]
Advances in Vaccines; Jeffrey Goad, PharmD, MPH / Vaccine Mythbusters; Daniel Solomon, MD

  • List newer vaccines and explain the importance/clinical relevance of their introduction
  • List recently updated/improved vaccine products and explain the importance/clinical relevance of those changes
  • Describe recent changes in ACIP guidelines and explain the rationale for those changes
  • List two or more common myths regarding standard immunizations (as recommended by ACIP)
  • Describe the sources of information antivaxers cite to justify their beliefs
  • Propose two or more arguments that might be effective in convincing doubtful patients to accept standard vaccinations

Disease State Guidelines Update [May 29, 3:30-5:00pm]
Asymptomatic Bacteriuria; Emily Spivak, MD, MHS / Community-acquired Pneumonia; Thomas File, MD

  • Describe the conditions and patient populations for asymptomatic bacteriuria
  • Discuss the issues and drawbacks to treating asymptomatic bacteriuria
  • List the instances where asymptomatic bacteriuria should be treated
  • Describe the overall management issues surrounding the treatment of CAP
  • Review the major changes in the CAP treatment guidelines
  • Discuss controversies that still remain to be answered regarding the treatment of CAP

Emerging and Difficult to Treat Infections [May 30, 8:00-9:30am]
Candida auris; Jeffrey Rybak, PharmD, PhD / Non-tuberculosis Mycobacteria; Wendy Bullington, PharmD

  • Describe the pharmacological and clinical consequences of antifungal resistance in Candida species
  • Identify epidemiological features associated with Candida auris
  • List infection control and treatment strategies suggested for suspected or known Candida auris
  • Explain the microbiology and epidemiology of nontuberculous mycobacterial lung disease (NTM-LD)
  • Outline major recommendations in diagnosis and monitoring of NTM-LD
  • Given a clinical scenario, describe how to implement evidence-based treatment recommendations for NTM-LD


Jeffrey A. Goad, PharmD, MPH, FISTM, FAPHA
Professor and Chair, Department of Pharmacy Practice
Chapman University School of Pharmacy
Irvine, CA

Daniel A. Solomon, MD
Associate Physician, Division of Infectious Diseases
Brigham and Women’s Hospital
Instructor of Medicine, Harvard Medical School
Boston, MA

Emily S. Spivak, MD, MHS, FIDSA
Medical Director, Antimicrobial Stewardship Programs
University of Utah Hospital, VA Salt Lake City Health Care System
Salt Lake City, UT

Thomas M File, Jr., MD, MSc, MACP, FIDSA, FCCP
Chair, Division of Infectious Disease, Summa Health
Akron, OH
Professor of Internal Medicine and Master Teacher
Chair Infectious Disease Section, Northeast Ohio Medical University (NEOMED)
Rootstown, OH

Jeffrey M. Rybak, PharmD, PhD
Postdoctoral Research Fellow, Rogers Lab, Department of Pharmacy Practice and Translational Sciences
UTHSC College of Pharmacy
Memphis, TN

Wendy Bullington, PharmD
Clinical Specialist, Pulmonary Medicine
Adjunct Associate Professor, Medical University of South Carolina
Charleston, SC

CE Accreditation


The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 05/27/2020 for this activity and is available for one year from this date.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Faculty disclosure will be announced through MAD-ID. 


This activity is provided by ProCE, Inc. and SIDP.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.